Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis reportPriya S. Kishnani, Yin‐Hsiu Chien, David Kronn et al.|Genetics in Medicine|2022Cited by 53
OP016: Mini-COMET: Safety and efficacy of ≥97 weeks’ avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfaDavid Kronn, On behalf of the Mini-COMET investigators, Satoko Kumada et al.|Genetics in Medicine|2022Cited by 10
The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase AlfaDavid Kronn, James Davison, Alexander Broomfield et al.|The Journal of Pediatrics|2025Cited by 3
Mini-COMET: Individual-level treatment responses in infantile-onset Pompe disease participants receiving avalglucosidase alfa or alglucosidase alfa who previously received alglucosidase alfaPriya S. Kishnani, David Kronn, Alexander Broomfield et al.|Molecular Genetics and Metabolism|2021Cited by 1
Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical declineDavid Kronn, Priya S. Kishnani, James Davison et al.|Molecular Genetics and Metabolism|2022Cited by 1